The content on this site is intended for healthcare professionals only
Prof Heinz Ludwig speaks to ecancer about a systematic review and meta-analysis comparing daratumumab- and isatuximab-based therapies in patients with newly diagnosed multiple myeloma.
He reports that both CD38-targeting monoclonal antibodies demonstrated broadly comparable efficacy, including overall response rates, depth of response, measurable residual disease negativity and progression-free survival.
Prof Ludwig explains that after adjusting for differences in control arm performance, daratumumab was associated with a higher overall response rate, while isatuximab was associated with fewer grade 3 or higher infections.
He also highlights that these findings may help inform treatment selection, although substantial differences between studies and the absence of direct head-to-head trials mean that further comparative research is needed.
First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML
First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma
Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab
Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma
Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome
Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM
Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM
Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma
IDH2 mutation associated with favourable outcome in older adults with newly diagnosed ALL treated with lower-intensity therapy
